{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T14:18:29Z","timestamp":1771337909442,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T00:00:00Z","timestamp":1632960000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T00:00:00Z","timestamp":1632960000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["24952"],"award-info":[{"award-number":["24952"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>To develop predictive models of side effect occurrence in GEPNET treated with PRRT. Metastatic GEPNETs patients treated in our centre with PRRT (177Lu-Oxodotreotide) from 2019 to 2020 were considered. Haematological, liver and renal toxicities were collected and graded according to CTCAE v5. Patients were grouped according with ECOG-PS, number of metastatic sites, previous treatment lines and therapies received before PRRT. A FLIC model with backward selection was used to detect the most relevant predictors. A subsampling approach was implemented to assess variable selection stability and model performance. Sixty-seven patients (31 males, 36 females, mean age 63) treated with PRRT were considered and followed up for 30\u00a0weeks from the beginning of the therapy. They were treated with PRRT as third or further lines in 34.3% of cases. All the patients showed at least one G1\u2013G2, meanwhile G3\u2013G5 were rare events. No renal G3\u2013G4 were reported. Line of PRRT administration, age, gender and ECOG-PS were the main predictors of haematological, liver and renal CTCAE. The model performance, expressed by AUC, was\u2009&gt;\u200965% for anaemia, creatinine and eGFR. The application of FLIC model can be useful to improve GEPNET decision-making, allowing clinicians to identify the better therapeutic sequence to avoid PRRT-related adverse events, on the basis of patient characteristics and previous treatment lines.<\/jats:p>","DOI":"10.1038\/s41598-021-99048-8","type":"journal-article","created":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T10:30:41Z","timestamp":1632997841000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Application of FLIC model to predict adverse events onset in neuroendocrine tumors treated with PRRT"],"prefix":"10.1038","volume":"11","author":[{"given":"Federica","family":"Scalorbi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Argiroffi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michela","family":"Baccini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Gherardini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Fuoco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie","family":"Prinzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Pusceddu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico Matteo","family":"Garanzini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Centonze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margarita","family":"Kirienko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ettore","family":"Seregni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Milione","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Maccauro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,30]]},"reference":[{"key":"99048_CR1","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","volume":"3","author":"A Dasari","year":"2017","unstructured":"Dasari, A. et al. Trends in the incidence, prevalence and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 3, 1335\u20131342 (2017).","journal-title":"JAMA Oncol."},{"key":"99048_CR2","doi-asserted-by":"publisher","first-page":"R153","DOI":"10.1530\/ERC-13-0125","volume":"21","author":"M Fraenkel","year":"2014","unstructured":"Fraenkel, M. et al. Incidence of gastro-enteropancreatic neuroendocrine tumours: A systematic review of the literature. Endocr. Relat. Cancer. 21, R153\u2013R163 (2014).","journal-title":"Endocr. Relat. Cancer."},{"key":"99048_CR3","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/s12020-017-1273-x","volume":"58","author":"E Leoncini","year":"2017","unstructured":"Leoncini, E. et al. Increased incidence trend of low-grade and high-grade neuroendocrine neoplasms. Endocrine 58, 368\u2013379 (2017).","journal-title":"Endocrine"},{"key":"99048_CR4","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1159\/000441897","volume":"104","author":"I Huguet","year":"2017","unstructured":"Huguet, I. et al. Changes in the epidemiology of neuroendocrine tumours. Neuroendocrinology 104, 105\u2013111 (2017).","journal-title":"Neuroendocrinology"},{"key":"99048_CR5","unstructured":"WHO Classification of Tumours Editorial Board; Digestive System Tumours, WHO Classification of Tumours. 5th ed. IARC Press. 2019."},{"issue":"1","key":"99048_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ecl.2010.12.005","volume":"40","author":"B Lawrence","year":"2011","unstructured":"Lawrence, B. et al. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol. Metab. Clin. N. Am. 40(1), 1\u201318. https:\/\/doi.org\/10.1016\/j.ecl.2010.12.005 (2011).","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"issue":"6","key":"99048_CR7","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1007\/s00268-011-1296-z","volume":"36","author":"O Norl\u00e9n","year":"2012","unstructured":"Norl\u00e9n, O. et al. Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center. World J. Surg. 36(6), 1419\u20131431. https:\/\/doi.org\/10.1007\/s00268-011-1296-z (2012).","journal-title":"World J. Surg."},{"key":"99048_CR8","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1677\/ERC-09-0042","volume":"16","author":"A Ahmed","year":"2009","unstructured":"Ahmed, A. et al. Midgut neuroendocrine tumours with liver metastasis: Results of the UKINETS study. Endocr. Relat. Cancer 16, 885\u2013894 (2009).","journal-title":"Endocr. Relat. Cancer"},{"issue":"2","key":"99048_CR9","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg, J. et al. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N. Engl. J. Med. 376(2), 125\u2013135. https:\/\/doi.org\/10.1056\/NEJMoa1607427 (2017).","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"99048_CR10","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/cas.13427","volume":"109","author":"N Fazio","year":"2018","unstructured":"Fazio, N. et al. Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis. Cancer Sci. 109(1), 174\u2013181. https:\/\/doi.org\/10.1111\/cas.13427 (2018).","journal-title":"Cancer Sci."},{"key":"99048_CR11","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1009290)","volume":"364","author":"JC Yao","year":"2011","unstructured":"Yao, J. C. et al. Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med. 364, 514\u2013523. https:\/\/doi.org\/10.1056\/NEJMoa1009290) (2011).","journal-title":"N. Engl. J. Med."},{"key":"99048_CR12","doi-asserted-by":"publisher","first-page":"9032753","DOI":"10.1155\/2019\/9032753","volume":"2019","author":"A Sahu","year":"2019","unstructured":"Sahu, A. et al. CAPTEM in metastatic well-differentiated intermediate to high grade neuroendocrine tumors: A single centre experience. J. Oncol. 2019, 9032753. https:\/\/doi.org\/10.1155\/2019\/9032753 (2019).","journal-title":"J. Oncol."},{"issue":"4","key":"99048_CR13","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1159\/000498887","volume":"108","author":"L De Mestier","year":"2019","unstructured":"De Mestier, L. et al. Comparison of temozolomide-capecitabine to 5-fluorouracile-dacarbazine in 247 patients with advanced digestive neuroendocrine tumors using propensity score analyses. Neuroendocrinology 108(4), 343\u2013353. https:\/\/doi.org\/10.1159\/000498887 (2019).","journal-title":"Neuroendocrinology"},{"key":"99048_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05236-z","author":"S Nicolini","year":"2021","unstructured":"Nicolini, S. et al. Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors. Eur. J. Nucl. Med. Mol. Imaging. https:\/\/doi.org\/10.1007\/s00259-021-05236-z (2021).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging."},{"issue":"16","key":"99048_CR15","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.1158\/1078-0432","volume":"23","author":"T Brabander","year":"2017","unstructured":"Brabander, T. et al. Long-term efficacy, survival, and safety of [177Lu-DOTA0, Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clin. Cancer Res. 23(16), 4617\u20134624. https:\/\/doi.org\/10.1158\/1078-0432 (2017).","journal-title":"Clin. Cancer Res."},{"key":"99048_CR16","unstructured":"Efficacy and safety of 177Lu-edotreotide PRRT in GEP-NET patients\u2014Full text view\u2014ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03049189."},{"key":"99048_CR17","unstructured":"Study to evaluate the efficacy and safety of Lutathera in patients with grade 2 and grade 3 advanced GEP-NET\u2014Full text view\u2014ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03972488."},{"key":"99048_CR18","unstructured":"Antitumor efficacy of peptide receptor radionuclide therapy with 177lutetium-octreotate randomized vs sunitinib in unresectable progressive well-differentiated neuroendocrine pancreatic tumor: First randomized phase II\u2014Full text view\u2014ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02230176."},{"issue":"7","key":"99048_CR19","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","volume":"31","author":"M Pavel","year":"2020","unstructured":"Pavel, M. Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 31(7), 844\u2013860. https:\/\/doi.org\/10.1016\/j.annonc.2020.03.304 (2020).","journal-title":"Ann Oncol."},{"key":"99048_CR20","unstructured":"Lutathera | European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/lutathera."},{"key":"99048_CR21","unstructured":"AGENZIA ITALIANA DEL FARMACO | DETERMINA 11 marzo 2019. https:\/\/www.aifa.gov.it\/documents\/20142\/847786\/Determina_501-2019_Lutathera.pdf."},{"key":"99048_CR22","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1186\/s12885-019-6000-y","volume":"19","author":"S Rudisile","year":"2019","unstructured":"Rudisile, S. et al. Salvage PRRT with 177Lu-DOTA-octreotate in extensively pre-treated patients with metastatic neuroendocrine tumor (NET): Dosimetry, toxicity, efficacy, and survival. BMC Cancer 19, 788. https:\/\/doi.org\/10.1186\/s12885-019-6000-y (2019).","journal-title":"BMC Cancer"},{"key":"99048_CR23","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1634\/theoncologist.2014-0037","volume":"19","author":"F Panzuto","year":"2014","unstructured":"Panzuto, F. et al. Real-world study of everolimus in advanced progressive neuroendocrine tumors. Oncologist 19, 966\u2013974 (2014).","journal-title":"Oncologist"},{"key":"99048_CR24","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1634\/theoncologist.2019-0743","volume":"25","author":"JM Heckert","year":"2020","unstructured":"Heckert, J. M. et al. Abnormal pre-treatment liver function tests are associated with discontinuation of peptide receptor radionuclide therapy in a U.S.-based Neuroendocrine Tumor Cohort. Oncologist 25, 572\u2013578 (2020).","journal-title":"Oncologist"},{"issue":"1","key":"99048_CR25","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00259-014-2893-5","volume":"42","author":"L Bodei","year":"2015","unstructured":"Bodei, L. et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: The value and limitations of clinical factors. EJNMMI 42(1), 5\u201319. https:\/\/doi.org\/10.1007\/s00259-014-2893-5 (2015).","journal-title":"EJNMMI"},{"issue":"2","key":"99048_CR26","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s12020-019-01894-0","volume":"66","author":"A Faggiano","year":"2019","unstructured":"Faggiano, A. et al. Therapeutic sequences in patients with grade 1\u20132 neuroendocrine tumors (NET): An observational multicenter study from the ELIOS group. Endocrine 66(2), 417\u2013424 (2019).","journal-title":"Endocrine"},{"key":"99048_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05332-0","author":"L Chen","year":"2021","unstructured":"Chen, L. et al. 177 Lu-DOTATATE in older patients with metastatic neuroendocrine tumours: Safety, efficacy and health-related quality of life. Eur. J. Nucl. Med. Mol. Imaging https:\/\/doi.org\/10.1007\/s00259-021-05332-0 (2021).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"4","key":"99048_CR28","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1093\/aje\/kwx299","volume":"187","author":"MA Mansournia","year":"2018","unstructured":"Mansournia, M. A., Geroldinger, A., Greenland, S. & Heinze, G. Separation in logistic regression: Causes, consequences and control. Am. J. Epidemiol. 187(4), 864\u2013870 (2018).","journal-title":"Am. J. Epidemiol."},{"key":"99048_CR29","unstructured":"Safety of Lanreotide 120 mg ATG in combination with metformin in patients with progressive advanced well-differentiated gastro-intestinal (gi) or lung carcinoids: A pilot, one-arm, open-label, prospective study\u2014Full Text View\u2014ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02823691."},{"key":"99048_CR30","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/biomet\/80.1.27","volume":"80","author":"D Firth","year":"1993","unstructured":"Firth, D. Bias reduction of maximum likelihood estimates. Biometrika 80, 27 (1993).","journal-title":"Biometrika"},{"issue":"14","key":"99048_CR31","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1002\/sim.7273","volume":"36","author":"R Puhr","year":"2017","unstructured":"Puhr, R., Heinze, G., Nold, M., Lusa, L. & Geroldinger, A. Firth\u2019s logistic regression with rare events: Accurate effect estimated and predictions?. Stat. Med. 36(14), 2302\u20132317 (2017).","journal-title":"Stat. Med."},{"issue":"1","key":"99048_CR32","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/biom.12381","volume":"72","author":"R De Bin","year":"2016","unstructured":"De Bin, R., Janitza, S., Sauerbrei, W. & Boulesteix, A. L. Subsampling versus bootstrapping in resampling-based model selection for multivariable regression. Biometrics 72(1), 272\u2013280. https:\/\/doi.org\/10.1111\/biom.12381 (2016).","journal-title":"Biometrics"},{"key":"99048_CR33","unstructured":"R: A language and environment for statistical computing. R Core Team, R Foundation for Statistical Computing, Vienna, Austria, 2019. https:\/\/www.R-project.org\/."},{"key":"99048_CR34","unstructured":"https:\/\/rdocumentation.org\/packages\/logistf\/versions\/1.24."},{"issue":"13","key":"99048_CR35","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","volume":"26","author":"DJ Kwekkeboom","year":"2008","unstructured":"Kwekkeboom, D. J. et al. Treatment With the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]Octreotate: Toxicity, efficacy, and survival. J. Clin. Oncol. 26(13), 2124\u20132130 (2008).","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"99048_CR36","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1159\/000506746","volume":"111","author":"K Fr\u00f6ss-Baron","year":"2021","unstructured":"Fr\u00f6ss-Baron, K. et al. 177Lu-DOTATATE therapy of advanced pancreatic neuroendocrine tumors heavily pretreated with chemotherapy: Analysis of outcome, safety, and their determinants. Neuroendocrinology 111(4), 330\u2013343 (2021).","journal-title":"Neuroendocrinology"},{"issue":"6","key":"99048_CR37","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1080\/0284186X.2020.1723161","volume":"59","author":"E Medaer","year":"2020","unstructured":"Medaer, E. et al. Influence of pretreatment with everolimus or sunitinib on the subacute hematotoxicity of 177Lu-DOTATATE PRRT. Acta Oncol. 59(6), 644\u2013651. https:\/\/doi.org\/10.1080\/0284186X.2020.1723161 (2020).","journal-title":"Acta Oncol."},{"issue":"3","key":"99048_CR38","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s00259-015-3193-4","volume":"43","author":"H Bergsma","year":"2016","unstructured":"Bergsma, H. et al. Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: Prognostic factors, incidence and course. Eur. J. Nucl. Med. Mol. Imaging. 43(3), 453\u2013463 (2016).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging."},{"issue":"3","key":"99048_CR39","doi-asserted-by":"publisher","first-page":"e0246691","DOI":"10.1371\/journal.pone.0246691","volume":"16","author":"JZ Qazi","year":"2021","unstructured":"Qazi, J. Z. et al. Predicting major bleeding among hospitalized patients using oral anticoagulants for atrial fibrillation after discharge. PLoS ONE 16(3), e0246691 (2021).","journal-title":"PLoS ONE"},{"key":"99048_CR40","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/s12871-019-0897-1","volume":"19","author":"S Mongoldi","year":"2019","unstructured":"Mongoldi, S. et al. Ten-year experience with standardized non-operating room anaesthesia with Sevoflurane for MRI in children affected by neuropsychiatric disorders. BMC Anesthesiol. 19, 235 (2019).","journal-title":"BMC Anesthesiol."},{"issue":"12","key":"99048_CR41","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1093\/aje\/kwt211","volume":"178","author":"C Zeng","year":"2013","unstructured":"Zeng, C. et al. Bias correction of risk estimates in vaccine safety studies with rare adverse events using a self-controlled case series design. Am. J. Epidemiol. 178(12), 1750\u20131759 (2013).","journal-title":"Am. J. Epidemiol."}],"updated-by":[{"DOI":"10.1038\/s41598-023-28977-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T00:00:00Z","timestamp":1675123200000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-99048-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-99048-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-99048-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T19:00:58Z","timestamp":1699556458000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-99048-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,30]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["99048"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-99048-8","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41598-023-28977-3","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,30]]},"assertion":[{"value":"5 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41598-023-28977-3","URL":"https:\/\/doi.org\/10.1038\/s41598-023-28977-3","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"FS, Marco Maccauro, Massimo Milione, ES, SP received honoraria as consultants and speakers from AAA, outside the submitted work. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19490"}}